PUBLISHER: Knowledge Sourcing Intelligence | PRODUCT CODE: 1649514
PUBLISHER: Knowledge Sourcing Intelligence | PRODUCT CODE: 1649514
The lumen apposing metal stent market is estimated at US$3.678 billion in 2025, and is expected to grow at a CAGR of 5.12%, attaining US$4.720 billion by 2030.
A lumen-apposing metal stent (LAMS) is a specialized device designed to enhance the scope of endoscopic interventions. Characterized by a dumbbell configuration and short saddle length, LAMS are specifically engineered to drain pancreatic fluid collections (PFCs) and address various gastrointestinal diseases. These stents offer significant advantages over traditional stents, particularly in terms of drainage efficiency, making them especially useful for conditions like walled-off necrosis. Additionally, LAMS have a reduced risk of migration and minimize the need for invasive procedures.The global market for lumen-apposing metal stents is expected to see substantial growth during the forecast period, primarily driven by the increasing incidence of inflammatory bowel diseases (IBD) worldwide. LAMS play a crucial role in managing IBD, particularly in cases of Crohn's disease, by providing effective monitoring and treatment options. The rising prevalence of gastrointestinal disorders is also anticipated to contribute to market growth.However, the expansion of the lumen-apposing metal stent market may face challenges due to the potential for side effects and the higher costs associated with these procedures. Generally, LAMS procedures are more expensive than traditional stent placements, and various clinical studies have shown minimal differences in outcomes between LAMS and conventional stents.
Drivers of the Lumen-Apposing Metal Stent Market
In managing IBD, lumen-apposing metal stents serve as an effective tool for addressing luminal gastrointestinal strictures in adults. Recent years have seen a notable increase in global cases of Crohn's disease. According to the National Center for Biotechnology Information, as of 2023, Canada reported approximately 825 cases of inflammatory bowel diseases per 100,000 individuals, with projections indicating a growth rate of 2.44% over the next decade. The total number of IBD cases in Canada is estimated to be around 320,000.Similarly, a report from Gastroenterology Advisor indicated that the prevalence of IBD in the USA has also risen significantly. In 2023, there were an estimated 2.39 million cases of IBD in the USA, including about 1.01 million cases of Crohn's disease and 1.25 million cases of ulcerative colitis. The prevalence rate was recorded at approximately 721 per 100,000 individuals in the USA.
Geographical Outlook
Additionally, government initiatives aimed at enhancing technological development in healthcare are expected to further boost market growth during this time frame. The increasing prevalence of inflammatory bowel disorders and gastrointestinal diseases in North America is also anticipated to drive market expansion. Research indicates that cases of IBD and gastrointestinal diseases are higher in this region compared to others, largely due to increased consumption of highly processed foods and lower fiber intake.
Reasons for buying this report:-
What do businesses use our reports for?
Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence